-
-
-
-
-
-
-
Lexeo phase I/II data for Friedreich ataxia gene therapy published
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) PT Lowered to $10 at H.C. Wainwright
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) PKP2-ACM Data Can Put Stock on Radars - Cantor Fitzgerald
-
-
-
-
-
-
-
Lexeo advances toward accelerated approval for gene therapy
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) Files for 41.63M Share Offering by Selling Stockholders
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) PT Raised to $23 at H.C. Wainwright
-
479,047 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


